PAG
ZNTL icon

Private Advisor Group’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Private Advisor Group’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$177K Buy
36,472
+5,000
+16% +$20K ﹤0.01% 2377
2026
Q1 		$73.6K Buy
+31,472
New +$81.3K ﹤0.01% 2559

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Private Advisor Group's ZNTL Position: Q2 2026 in Review

Private Advisor Group increased its Zentalis Pharmaceuticals (ZNTL) stake by 16% in Q2 2026, buying an estimated $20K and bringing the position to 36,472 shares worth $177K. The position accounts for ﹤0.01% of the portfolio, ranked #2377.

Private Advisor Group first reported a position in ZNTL in Q1 2026 and has held it in 2 quarters since. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Private Advisor Group held 36,472 shares of Zentalis Pharmaceuticals worth $177K as of Q2 2026.
  • Private Advisor Group bought 5,000 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $20K.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Private Advisor Group's portfolio in Q2 2026, its #2377 holding.
  • Private Advisor Group first reported a position in Zentalis Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Private Advisor Group's 13F filing for Q2 2026, filed 27 Jul 2026.